Uric acid, allopurinol therapy, and mortality in patients with acute heart failure—results of the Acute HEart FAilure Database registry

Málek, Filip; Ošťádal, Petr; Pařenica, Jiří; Jarkovský, Jiří; Vítovec, Jiří; Widimský, Petr; Linhart, Aleš; Fedorco, Marián; Coufal, Zdeněk; Miklík, Roman; Krüger, Andreas; Vondráková, Dagmar; Špinar, Jindřich

doi:10.1016/j.jcrc.2012.03.011

Cited by 41 publications

(45 citation statements)

References 24 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Málek et al, however, noted the conflicting result that hyperuricemia was related to long-term mortality only in subjects with eGFR=30-60 ml/min/1.73 m 2 but not in those with eGFR <30 or >60 ml/min/1.73 m 2 . 10 In the present study, we demonstrated an obvious attenuation of prediction of long-term mortality for uric acid level with deteriorating renal function in patients with AHF, which was consistent with the majority of published data in patients with CHF. The results suggest that hyperuricemia in patients with CKD has a more complex relationship.…”

Section: Study Limitationssupporting

confidence: 92%

“…7 Although hyperuricemia was related to short-term and long-term mortality, the independence of the prognostic value of uric acid levels was not evaluated on multivariate modeling in the Málek et al study. 10 Figure 2. Kaplan-Meier survival curve analysis according to uric acid quartile, in patients with reduced left ventricular ejection fraction (LVEF; quartile 1, <7.0 mg/dl; quartile 2, 7.0-9.0 mg/dl; quartile 3, 9.0-11.0 mg/dl; and quartile 4, ≥11.0 mg/dl); and patients with preserved LVEF (quartile 1, <6.4 mg/dl; quartile 2, 6.4-8.0 mg/dl; quartile 3, 8.0-9.9 mg/dl; and quartile 4, ≥9.9 mg/dl).…”

Section: Hyperuricemia and Ckdmentioning

confidence: 99%

See 1 more Smart Citation

Determinants and Prognostic Impact of Hyperuricemia in Hospitalization for Acute Heart Failure

Huang

Hsu

Cheng

et al. 2016

Circ J

View full text Add to dashboard Cite

Section: Study Limitationssupporting

confidence: 92%

Section: Hyperuricemia and Ckdmentioning

confidence: 99%

Determinants and Prognostic Impact of Hyperuricemia in Hospitalization for Acute Heart Failure

Huang

Hsu

Cheng

et al. 2016

Circ J

View full text Add to dashboard Cite

“…3,7,10,11 Although controversial, the use of allopurinol in patients with asymptomatic hyperuricemia has been increasing worldwide in recent years. [12][13][14][15][16] Prescriptions of allopurinol to patients having asymptomatic hyperuricemia with cardiovascular, renal, or metabolic diseases may be based on the assumption that high levels of serum uric acid contribute to the prognosis of these disorders. [12][13][14][15][16] However, the overall risks of allopurinol use in asymptomatic hyperuricemia remain unclear.…”

mentioning

confidence: 99%

Allopurinol Use and Risk of Fatal Hypersensitivity Reactions

et al. 2015

View full text Add to dashboard Cite

“…Previously reports have been predominantly elucidated a relationship between cardiovascular outcomes and documented hyperuricemia in patients with acute and chronic heart failure [3,21,22]. The effects of SUA on all-cause mortality at different SUA cut-offs in CHF patient population was evaluated using meta-regression.…”

Section: Discussionmentioning

confidence: 99%

The relationship between serum uric acid level and concentration of proangiogenic mononuclear progenitor cells in patients with chronic heart failure

Berezin

Kremzer²

2014

J Clin Exp Invest

View full text Add to dashboard Cite

ÖZETAmaç: Serum ürik asit (ÜA) kronik kap yetmezliğinin (KKY) doğal ilerleyişinin bir belirteci olarak bilinir. KKY ilerlemesi kanda dolaşan mononükleer projenitör hücrele-rin (MPH) azalması ile birliktedir. Bu çalışmanın amacı iskemik KKY'li hasatlarda serum ÜA ve proanjiyojenik MPH konsantrasyonları arasındaki ilişkiyi değerlendirmektir.Yöntemler: Bu çalışma kontrastlı bilgisayarlı tomografi anjiyografisi ile koroner arter hastalığı (KAH) tanısı alan KKY'li 126 hastada (54 erkek)retrospektif olarak yapıl-mıştır. Serum ÜA enzimatik yöntemle ve N-terminal proB-NP (NT-pro-BNP) düzeyi immünoelektrokemilüminesens yöntemi ile çalışıldı. Bulgular: Serum ÜA konsantrasyonları kuartallar olarak değerlendirildi (Me; IQR): QI=20.11 (19.06; 22.33) mmol/l; QII=27.53 (23.2; 31.10) mmol/l; QIII=35.80 (32.0; 39.0) mmol/l ve QIV=44.9 (40.00; 49.60) mmol/l. Serum ÜA'e göre düzeltilmiş Cox oransal Odds oranı analizleri CD14+CD309+ ve CD14+CD309+Tie2+ MPH için SUA Quartiles (Q) ile yapıldı ve Yüksek serum ÜA Q (Q3 ve Q4) ve düşük Q (Q1 ve Q2)'nin artmış CD14+CD309+ ve CD14+CD309+Tie2+ MPH tükenme riski ile birlikte olduğu gösterildi. ROC analizi ile serum ÜA 31,5 mmol/l değeri MPH azalma riski için en iyi potansiyel cut-off değeri olarak belirlendi.Sonuç: Konjestif kalp yetmezliği bulunan hastalarda dolaşan proanjiyojenik MPH, serum ÜA kuartallarına bağlı olarak ilerleyici bir şekilde azaldı. Serum ÜA'de hafif artı-şın düşük proanjiyojenik MPH'nin bir öngördürücüsü olarak kabul edilebilir.Anahtar kelimeler: Kronik kalp yetmezliği, serum ürik asit, dolaşan mononükleer projenitör hücreler, prediktif değer ABSTRACT Objective: Serum uric acid (UA) is considered as a marker of natural progression of chronic heart failure (CHF). Progression of CHF associates with declining of circulating mononuclear progenitor cells (MPCs) in the blood. The objective of this study was to evaluate the interrelationship between SUA concentrations and proangiogenic MPCs in ischemic CHF patients. Methods:The study was structured retrospectively after determining the coronary artery disease (CAD) by contrast-enhanced spiral computed tomography angiography in 126 subjects (54 male), aged 48 to 62 years, with CHF. Serum UA level was measured by enzymatic method and N-terminal proBNP (NT-pro-BNP) level was examined by immunoelectrochemiluminesence method. All biomarkers were measured at baseline. Results:Concentrations of SUA were distributed by quartiles (Me; IQR): QI=20.11 (19.06; 22.33) mmol/l; QII=27.53 (23.2; 31.10) mmol/l; QIII=35.80 (32.0; 39.0) mmol/l; and QIV=44.9 (40.00; 49.60) mmol/l. Cox proportional adjusted Odds Ratios analyses for CD14+CD309+ and CD14+CD309+Tie2+ MPCs by SUA Quartiles (Q) has showed that high Q (Q3 and Q4) of SUA versus low Q (Q1 and Q2) associated with increased risk of depletion of both CD14+CD309+ and CD14+CD309+Tie2+ MPCs. The ROC analysis has been showed that there was the cut-off point for the SUA level with the best prognostic potential on the risk of decreasing MPCs in both models equal 31.5 mmol/l. Conclusion:Circulate...

show abstract

Uric acid, allopurinol therapy, and mortality in patients with acute heart failure—results of the Acute HEart FAilure Database registry

Cited by 41 publications

References 24 publications

Determinants and Prognostic Impact of Hyperuricemia in Hospitalization for Acute Heart Failure

Determinants and Prognostic Impact of Hyperuricemia in Hospitalization for Acute Heart Failure

Allopurinol Use and Risk of Fatal Hypersensitivity Reactions

The relationship between serum uric acid level and concentration of proangiogenic mononuclear progenitor cells in patients with chronic heart failure

Contact Info

Product

Resources

About